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We report in vitro characterization of 11 SIVsmm strains of six lineages co-circulating in naturally infected sooty mangabeys (SMs) from US
Primate Centers and showed no major differences in the in vitro replication pattern between different SIVsmm lineages. Primary SIVsmm isolates
utilized CCR5 and Bonzo co-receptors in vitro. SIVsmm growth in human T cell lines was isolate-, not lineage-specific, with poor replication on
Molt4-Clone8, CEMss and PM1 cells and better replication on MT2, SupT1 and CEMx174 cells. All primary SIVsmm isolates replicated on SM
and human PBMCs. In vitro replication in macaques varied widely, with moderate to high replication in pig-tailed macaque PBMCs, enhanced by
CD8+ T cell depletion, and highly variable replication on rhesus macaque (Rh) PBMCs. Primary SIVsmm isolates replicated in Rh monocyte-
derived dendritic cells (MDDCs) and monocyte-derived macrophages (MDMs). In vivo, SIVsmm isolates replicated at high levels in all SIVsmm-
infected Rh. The poor in vitro replication of primary SIVsmm isolates in Rh cells did not correlate with in vivo replication, emphasizing the value
of in vivo studies.
© 2007 Elsevier Inc. All rights reserved.Keywords: SIVsmm; Rhesus macaque; In vitro replication; Sooty mangabey; PathogenesisIntroduction
SIVsmm naturally infects sooty mangabeys (SMs Cercoce-
bus atys) (Apetrei et al., 2005b; Chen et al., 1996; Hirsch et al.,
1989b; Marx et al., 1991; Peeters et al., 1994; Santiago et al.,
2005) and is genetically closely related to HIV-2 (Chen et al.,⁎ Corresponding author. Division of Microbiology, Tulane National Primate
Research Center, 18703 Three Rivers Road, Covington LA 70433, USA. Fax:
+1 985 871 6248.
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doi:10.1016/j.virol.2006.12.0371997a; Damond et al., 2004; Gao et al., 1992, 1994; Yamaguchi
et al., 2000) and SIVmac (Chakrabarti et al., 1987). Phylogenetic
analyses and geographic coincidence support the idea that
multiple cross-species transmission events from SMs to humans
gave rise to HIV-2 (Chen et al., 1997a; Damond et al., 2004; Gao
et al., 1992, 1994; Yamaguchi et al., 2000). Accidental or
experimental cross-species transmission of SIVsmm to macaque
species is the origin of SIVmac/mne and SIVstm (Apetrei et al.,
2006; Khan et al., 1991; Lowenstine et al., 1992; Mansfield et
al., 1995; Murphey-Corb et al., 1986). In the new hosts, cross-
species transmitted viruses show pathogenic potential. Thus,
Fig. 1. Primary SIVsmm isolates replication in sooty mangabey PBMCs.
SIVsmm strains belonging to different lineages are color-coded (red—Lineage
1; purple—Lineage 2; turquoise—Lineage 3; blue—Lineage 4; orange—
Lineage 5; light green—Lineage 6).
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develop profound immune suppression within 2 years of
infection (Smith et al., 1999; Westmoreland et al., 1998). SIV
disease progression is even more rapid in pig-tailed macaques
(PTMs) (Hirsch and Johnson, 1994). Humans infected with
HIV-2 also progress to AIDS, although the incubation period is
longer than that of HIV-1 (Simon et al., 1993). Therefore, it is a
widely held belief that SIVsmm is highly pathogenic upon
cross-species transmission. However, one should note that the
eight cross-species transmission events documented in humans
had unbalanced epidemiologic consequences, with only two
epidemiologically successful cross-species transmissions gen-
erating the epidemic groups HIV-2 A and HIV-2 B (Damond et
al., 2001; Gao et al., 1994). Groups C-H of HIV-2 (Chen et al.,
1997a; Damond et al., 2004; Gao et al., 1994; Yamaguchi et al.,
2000) are weakly pathogenic, non-epidemic strains that
replicate poorly in infected humans and are found only within
the range of SMs or in persons who emigrated from Western
Africa (Chen et al., 1997a; Gao et al., 1994). Therefore, it
appears that cross-species transmission is not the only
requirement for HIV emergence and additional effects, such as
viral adaptation through serial passages, may have contributed
to successful adaptation of HIV-2 into its new host (Apetrei and
Marx, 2004; Drucker et al., 2001). This was clearly demon-
strated in the case of SIVmac/SIVsmm strains, for which the
increase in pathogenicity was associated with serial passage
(Apetrei et al., 2006; Hirsch et al., 1997; Mansfield et al., 1995).
In SMs, chronic SIVsmm infection is generally not associated
with disease despite high viral loads (Rey-Cuille et al., 1998;
Silvestri, 2005; Silvestri et al., 2003, 2005). Different mechan-
isms have been associated with this absence of pathogenicity,
and a recent consensus currently states that the lack of SIV
disease progression in SMs is due to an effective control of
immune activation and proliferation (Chakrabarti et al., 2000;
Dunham et al., 2006; Silvestri et al., 2003, 2005). SIVsmm was
recently shown to induce AIDS both in the host species (SM)
(Ling et al., 2004) and in another African non-human primate
host, the black mangabey, upon cross-species transmission
(Apetrei et al., 2004).
During our previous studies, we did extensive genetic
characterization of SIVsmm diversity in SM colonies in the
United States and showed the co-circulation of 9 genetic
clusters. Two of these lineages were the ancestral lineages of the
macaque reference strains SIVmac and SIVstm (Apetrei et al.,
2005a; Ling et al., 2003). These clusters originated from the
transmission of SIVsmm founder viruses from SMs naturally
infected before importation (Apetrei et al., 2005a). Most of these
SIVsmm lineages went undetected until our initial studies in
2003 (Ling et al., 2003). Three lineages (including the two that
generated SIVmac/mne and SIVstm) are currently extinct in
American colonies. However, the co-circulation of highly
divergent viruses in SMs offer opportunities for comparative
pathogenesis and vaccine studies since these SIVsmm lineages
show the same degree of divergence as HIV-1 subtypes (Apetrei
et al., 2005a).
Although SIVsmm was the first virus isolated from natural
African NHP hosts of SIVs (Fultz et al., 1986; Murphey-Corb etal., 1986), and is the root source of the extensively used strains
characterized in the macaque model for AIDS (Apetrei et al.,
2005a; Hirsch et al., 1997; Letvin, 1990), very few available
reports address the in vitro replicative capacities of primary
SIVsmm isolates. Most studies carried out thus far utilize strains
heavily adapted for use in the laboratory or in macaques. It was
reported that SIVsmm strains primarily use chemokine co-
receptor CCR5, although some strains can also use CXCR4
(Chen et al., 1997b; Owen et al., 2000; Zhang et al., 2000).
SIVsmm was shown to efficiently infect in vitro human
peripheral blood mononuclear cells (PBMCs) (Chen et al.,
1995; Hirsch et al., 1989a) and monocyte-derived macrophages
(MDMs) (Grimm et al., 2003). This is in agreement with
molecular epidemiology data showing that this virus crossed the
species barrier into humans eight times during the last century
(Damond et al., 2004; Hahn et al., 2000). In vitro replication of
SIVsmm in human T cell lines is variable and the efficacy of
growth increase for SIVsmm strains that have been serially
passaged in macaques (Fultz et al., 1986, 1989).
In this study we have performed a thorough in vitro char-
acterization of currently available SIVsmm primary isolates
belonging to 6 different phylogenetic lineages (Apetrei et al.,
2005a). We show here that there are no discernable differences
in the in vitro replication capacities between different SIVsmm
lineages. We also show that Rh PBMCs vary greatly in their
ability to support in vitro replication of primary SIVsmm
isolates. Finally, we demonstrated that this in vitro variability of
viral replication is not paralleled by in vivo replication patterns.
Results
Stock preparation
To obtain viral stocks for further in vitro studies, primary
SIVsmm isolates belonging to different lineages were first
propagated in vitro on SM PBMCs. Results are showed in Fig. 1.
All but two SIVsmm strains grew rapidly and at high titers in SM
PBMCs. Significant P27 Ag production was observed starting
Table 1
In vitro growth of primary SIVsm isolates belonging to different lineages on
human cell lines
MT2 SupT1 CEMx174 CEMss PM1 Molt4
Clone8
Lineage 1 M919 +++1
(w52)
+++(w3) ++(w8) – – –
M935 +++(w5) +++(w6) +++(w8) – +(w4) –
M923 ++(w6) – +(w4) – – –
Lineage 2 M926 NT NT +++(w6) NT ±(w4) –
M946 +++(w4) +++(w6) +++(w3) – – –
Lineage 3 M949 – – +++(w5) – – –
M951 – ±(w6) +++(w6) – – –
Lineage 4 M932 +++(w6) – +++(w5) – – –
Lineage 6 D215 – +++(w7) +++(w6) – +(w5) –
1Defined based on P27 antigen concentration at the peak of viral replication
(noted in the parenthesis); ±, 30–100 pg; +, 100–500 pg; ++, 501–2000 pg; +++,
>2000 pg per well; 2w=week post cell inoculation.
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at low levels on SM PBMCs. SIVsmmM935 (Lineage 1)
replicated at moderate levels on SM PBMCs (Fig. 1). All the
isolates showed cytopathic effects on SM cells. There was no
discernable difference in the in vitro replication profiles on SM
PBMCs between strains belonging to different lineages. Super-
natants from these positive SM PBMC cultures were used as
viral stocks for further experiments.
Use of CCR5 and STRL33 is a common feature of SIVsm
The previously characterized SIVsmm strains utilized CCR5
as their major co-receptor (Chen et al., 1998a; Zhang et al.,
2000), and, to a lesser extent, CXCR4 (Owen et al., 2000).
Therefore, to investigate the differences in viral replication
between primary SIVsmm isolates, co-receptor usage was
determined using the GHOST cell assay, focusing on the major
co-receptors: CCR5, CXCR4, CCR2B, CCR3, STRL33
(Bonzo), and GPR15 (Bob) (Fig. 2). Replication capacity in
GHOST cell lines, as assessed by supernatant P27 Ag activity,
showed no qualitative differences in co-receptor usage between
SIVsmm strains belonging to different lineages. Our results
showed that most of the primary SIVsmm isolates tested here
used CCR5 and STRL33; primary SIVsmm isolates also used
to a lesser extent GPR15, but did not utilize CCR3, CCR2b, or
CXCR4, thus confirming previous reports on co-receptor usage
of SIVsmm (Chen et al., 1998a; Zhang et al., 2000). Some
strains showed reactivity above background level on CXCR4
cells, that was isolate-related, rather than lineage-related (Fig.
2). This experiment showed that the differences in pathogeni-
city between primary SIVsmm isolates and reference strains in
Rh are apparently not due to differences in co-receptor use.
Primary SIVsmm isolate growth profile on Hu-derived cell
lines
All the primary SIVsmm isolates were tested for their ability
to replicate on different Hu cell lines and the results are shown inFig. 2. Co-receptor usage of primary SIVsmm isolates belonging to 6 different lineag
lineages are color-coded (red—Lineage 1; purple—Lineage 2; turquoise—Lineage
SIVmac239).Table 1. All of the tested strains replicated slowly on CEMx174
cells. Detectable amounts of viral antigen were seen only after
3 weeks post-inoculation. In most cases, cultures became
positive very late after the inoculation (>w6 for 5 strains). In
the T cell lines, there were differences in viral growth between
the different strains. Strains SIVsmmM919, SIVsmmM935
(lineage 1), SIVsmmM946 (lineage 2), SIVsmmM951 (lineage
3), and SIVsmmD215 (lineage 6) grew on SupT1. OnMT2 cells,
three isolates showed no sign of replication [SIVsmmM949 and
SIVsmmM951 (lineage 3), and SIVsmmD215 (lineage 6)],
while other isolates [SIVsmmM919, SIVsmmM935,
SIVsmmM923 (lineage 1), SIVsmmG932 (lineage 4), and
SIVsmmM946 (lineage 2)] showed efficient, although delayed
(w4 to w6), replication. Only three strains [SIVsmmM935
(lineage 1), SIVsmmM926 (lineage2), and SIVsmmD215
(lineage 6)] replicated at low titers on PM1 cells. None of the
viruses replicated on Molt4-Clone8 or CEMss cells. Altogether,
these results show that primary SIVsmm isolates have a variable
tropism on human T cell lines. This experiment showed that
although strain-related differences were observed in thises, as measured at day 6 post-inoculation. SIVsmm strains belonging to different
3; blue—Lineage 4; orange—Lineage 5; light green—Lineage 6; yellow—
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replication pattern on human T cell lines for SIVsmm lineages.
Primary SIVsmm isolate growth profiles in Hu PBMCs
The ability of primary SIVsmm isolates to replicate on
human cells was further tested on both Hu PBMC, and
CD8+-depleted Hu PBMCs. All the viruses replicated
efficiently in Hu PBMC as well as in CD8+-depleted Hu
PBMCs. All but one (SIVsmmM940) cultures showed
detectable P27 Ag after day 7 post-inoculation. P27 levels
at the peak of antigen production ranged from 7000 to
8000 pg. Lineage 3 strains grew slower on both Hu PBMCs
and CD8+-depleted Hu PBMCs (Figs. 3a and b). Strain
SIVsmmFTq (lineage 5) grew slower than the other strains on
CD8+-depleted Hu PBMCs. However, this difference was not
observed on undepleted Hu PBMCs, in which SIVsmmFTq
replicated similarly to other primary SIVsmm isolates. Again,
these results showed no significant difference in primary
SIVsmm isolates ability to infect Hu PBMCs in vitro and
confirmed previous reports indicating that SIVsm, the source
virus of HIV-2 (Chen et al., 1997a; Gao et al., 1992, 1994;
Marx et al., 1991), replicates efficiently on Hu PBMCs.Fig. 3. Primary SIVsmm isolate replication in Human (Hu) PBMCs (a), CD8+-deplet
PBMCs (d). SIVsmm strains belonging to different lineages are color-coded (red—Li
Lineage 5; light green—Lineage 6).Primary SIVsmm isolate growth profiles in PTM PBMCs
PTM PBMCs and CD8+-depleted PTM PBMCs were used
to replicate primary SIVsmm strains. Total PTM PBMCs
supported only limited replication of primary SIVsmm isolates.
Only six out of ten strains were isolated on PTM PBMCs, and
only at low P27 Ag levels, ranging from 100 to 1500 pg (Fig.
3c). Strains SIVsmmM919 (lineage 1), SIVsmmM951,
SIVsmmM940 (both lineage 3) and SIVsmmD215 (lineage 6)
did not replicate on the PTM PBMCs. Conversely, CD8+-
depleted PTM PBMCs from the same animal supported
SIVsmm replication for all but two (M919 and D215) primary
SIVsmm isolates (Fig. 3d). Moreover, CD8+-depleted PTM
PBMCs had significantly higher levels of SIVsmm replication
compared to non-CD8+-depleted PTM PBMCs, ranging from
3000 to over 7000 pg/ml. However, the highest viral replication
in CD8+depleted PTM PBMC occurred at later time points than
in SM-PBMCs (Fig. 1) or Hu-PBMCs (Figs. 3a and b).
Variable growth of primary SIVsmm isolates in Rh PBMCs
The first attempts to replicate primary SIVsmm isolates in
Rh PBMCs were unsuccessful. None of the tested strainsed Hu PBMCs (b), pig-tailed macaque (PTM) PBMCs (c), CD8+-depleted PTM
neage 1; purple—Lineage 2; turquoise—Lineage 3; blue—Lineage 4; orange—
261R. Gautam et al. / Virology 362 (2007) 257–270replicated on PBMCs from 3 different Rh (data not shown).
This result was unexpected, since all Rh inoculated with
macaque-passaged SIVsmm strains replicate the virus and
eventually progress to AIDS (Hirsch and Johnson, 1994).
Therefore, a detailed analysis of the in vitro replication profiles
of primary SIVsmm isolates on a large number of animals was
performed.
In the first step, Rh PBMCs from three different Rh (DV11,
DD51, and AJ31) were CD8+-depleted and inoculated with ten
primary SIVsmm isolates belonging to six different lineages.
Results are shown in Figs. 4a, b, and c. In vitro replication
profiles varied between the different animals. CD8+-depleted
PBMCs from DV11 supported the replication of all but one
(SIVsmmM919-lineage 1) strain. Two strains (SIVsmmFTq-Fig. 4. Primary SIVsmm replication in CD8+-depleted PBMCs from 3 rhesus
macaques (Rh): RhDV11 (a); RhDV51 (b); RhAJ31 (c). SIVsmm strains
belonging to different lineages are color-coded (red—Lineage 1; purple—
Lineage 2; turquoise—Lineage 3; blue—Lineage 4; orange—Lineage 5; light
green—Lineage 6).lineage 5 and SIVsmmM935-lineage 1) replicated at lower titers
compared to the remaining strains (Fig. 4a). All but one
(SIVsmmFTq) strain replicated at high levels on CD8+-depleted
PBMCs fromDD51 (Fig. 4b). Finally, all but one (SIVsmmM935)
strain replicated on CD8+-depleted PBMCs from AJ31 (Fig. 4c).
Strains SIVsmmG932 (lineage 4), SIVsmmFTq (lineage 5) and
SIVsmmM919 (lineage 1) replicated at lower levels compared to
the remaining strains (Fig. 4c). These results suggested a certain
variability of the in vitro replication of primary SIVsmm isolates
on Rh PBMCs.
Since such variability was not observed in previous
experiments on human, SM, or PTM PBMCs, we extended
this experiment to include a significant number of Rh. Total
PBMCs from ten different Rh were used in a chess-board
testing using nine primary SIVsmm isolates and SIVmac239
as a control. Results are shown in Fig. 5a. Primary SIVsmm
isolates showed a variable replication pattern, dependent on
the animal used for in vitro cultures, that ranged from
complete or almost complete replication support (BV48 and
AN21) to complete restriction (R186). Quantitative replication
patterns of primary SIVsmm isolates on Rh PBMCs also
varied widely between different Rh (Fig. 5a). This comparative
in vitro study also showed that lineage 1 and lineage 3 strains
are able to replicate better in vitro on Rh PBMCs compared to
the other lineages (Fig. 5a). Differently from primary SIVsmm
isolates, serially passaged SIVmac239 replicated in all Rh
(Fig. 5a).
Finally, in order to confirm that this variable viral replication
on Rh PBMCs is characteristic for Rh, we have detailed the in
vitro replication of SIVsmm on Hu PBMCs. Total PBMCs
from nine different Hu blood donors were used in a chess-
board testing using nine primary SIVsmm isolates. Results are
shown in Fig. 5b. As it can be observed from this figure,
although the viral replication patterns varied between the
different blood donors, all the primary SIVsmm isolates were
consistently replicated in vitro using Hu PBMCs from blood
donors (Fig. 5b).
Primary SIVsmm isolates grow at low levels in Rh MDDCs
Dendritic cells are antigen-presenting cells that are
susceptible to HIV-1 infection (Donaghy et al., 2003). Since
MDDCs were reported to enhance CD4+ T cell infection
(McDonald et al., 2003), we investigated the ability of primary
SIVsmm isolates to grow on MDDCs from Rh in order to
understand the differences observed between in vitro and in
vivo replication patterns. As observed from Fig. 6a, MDDC
supported the in vitro replication of primary SIVsmm isolates.
The replication levels were, however, very low (100–400 pg
P27 Ag), in agreement with previous reports on HIV-1 growth
in MDDCs (Donaghy et al., 2003). Only strain SIVsmmM926
showed a replication pattern that was indistinguishable from
baseline levels (Fig. 6a). To confirm SIVsmm replication on
the MDDCs, infected MDDCs were co-cultivated with
autologous CD8+-depleted PBMCs. As it can be observed
from Fig. 6b, all cultures became positive, with the exception
of SIVsmmM935, which only showed a low blip at day 15
Fig. 5. Variable susceptibility of Rh PBMCs to primary SIVsmm isolates belonging to different lineages (a), as compared to consistent susceptibility of Hu-PBMCs.
SIVsmm strains belonging to different lineages are color-coded (red—Lineage 1; purple—Lineage 2; turquoise—Lineage 3; blue—Lineage 4; orange—Lineage 5;
light green—Lineage 6). White lines represent the dynamics of in vivo replication at different time points post-inoculation (days 0, 7, 10, 14, 21, or 28 p.i.). Vertical
scale ranges from 0 to 8000 pg of P27 Ag. White squares signify no in vitro growth.
262 R. Gautam et al. / Virology 362 (2007) 257–270post-innoculation. This experiment demonstrated the ability of
primary SIVsmm isolates to replicate in Rh MDDCs. More-
over, our co-culture experiment demonstrated that prior
exposure of DCs to SIVsmm can increase the efficacy of
SIVsmm isolation in vitro.
Primary SIVsmm isolates show variable growth in Rh MDMs
Macrophages may play a pivotal role in SIV infection and
some SIV strains are macrophage tropic (Grimm et al., 2003).
Macrophage tropism is almost exclusively linked to use of the
chemokine co-receptor CCR5 (Moore et al., 2004). However,
CCR5 tropism is sometimes not sufficient for replication inmacrophages (e.g. SIVmac239) (Moore et al., 2004). Since our
SIVsmm strains belonging to different lineages also use the
CCR5 co-receptor, we investigated a potential role of MDMs
in Rh infection with primary SIVsmm isolates. Over a 3-week
period, ten primary SIVsmm isolates were grown in Rh MDMs
(Fig. 6c). Seven SIVsmm strains replicated productively in
MDMs, whereas measurable antigen production was not
observed for the remaining three [SIVsmmM919 and
SIVsmmM935 (lineage 1) and SIVsmmFTQ (lineage 5)].
The extent of replication in Rh MDMs was variable between
different isolates and lineages. Thus, lineage 6 (SIVsmmD215)
and lineage 2 (SIVsmmM926 and SIVsmmM946) replicated at
the highest levels in Rh MDMs (Fig. 6c). Lineage 3
Fig. 6. Primary SIVsmm isolate replication on Rh MDDC cultures (a), CD8+-depleted Rh PBMCs following co-cultivation with SIV-infected MDDC (b); Rh
monocyte-derived macrophages (MDMs) (c); and on MDMs+ CD8+-depleted Rh PBMCs (d). SIVsmm strains belonging to different lineages are color-coded (red—
Lineage 1; purple—Lineage 2; turquoise—Lineage 3; blue—Lineage 4; orange—Lineage 5; light green—Lineage 6).
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(SIVsmmG932) strains replicated at lower levels. Surprisingly,
although lineage 1 is the most pathogenic in vivo in Rh
(McClure et al., 1989) (Apetrei, unpublished data), two out the
three lineage 1 strains did not replicate on Rh MDMs, and the
remaining strain only showed moderate levels of growth.
When SIVsmm-infected macrophages were co-cultured with
CD8+-depleted PBMCs, all ten virus strains showed significant
levels of replication (Fig. 6d). The three isolates which did not
show detectable levels of replication in MDM alone, replicated
fairly well when co-cultured with autologous CD8+-depleted
cells (Fig. 6d). This experiment confirmed the ability of
primary SIVsmm isolates to replicate in Rh MDMs in vitro
(Hirsch et al., 1997).
No correlation between the in vitro growth pattern in Rh and
the in vivo viral replication
Our results showing a limited in vitro replication of
primary SIVsmm on Rh PBMCs were surprising because
SIVsmm is a virus which is pathogenic in Rh upon in vivo
innoculation in all exposed Rh (Hirsch and Johnson, 1994).
Therefore, in order to understand if variability in in vitro
replication of primary SIVsmm isolates on Rh PBMCs has
any impact on viral replication in vivo, we compared viral
replication in Rh in vivo and in vitro on a significant group ofanimals. In this experiment used PBMCs sampled prior to
SIVsmm infection to grew in vitro the SIVsmm strains which
were employed for in vivo infection and we compared the in
vivo and in vitro replication. Results are presented in Fig. 7.
The different SIVsmm strains replicated efficiently in vivo in
all exposed animals, generating high levels of P27 antigene-
mia (Fig. 7a), with the dynamics of plasma viral loads
paralleling that of P27 antigenemia and being in the same
range with those observed during pathogenic infections with
reference SIVmac/SIVsmm strains (Fig. 7b). However, the in
vitro replication was again variable. Only 38% of cultures of
SIVsmm strains on Rh PBMCs from the same animals which
were used for experimental infections were positive. Lineage 1
(SIVsmmM923) and lineage 3 (SIVsmmM951) strains did not
replicate in the PBMCs from the Rh that they infected
successfully in vivo. Half of the cultures were positive for
monkeys infected with the lineage 2 (SIVsmmM946) and
lineage 6 (SIVsmmD215) strains. Only one out of three
cultures was positive for SIVsmmFTq. Rh AT30 which was
infected with SIVsmmG932 (lineage 4) replicated the virus at
high titers. Another difference in the in vitro growth is that, in
the positive cultures, strains SIVsmmM946, SIVsmmG932,
and SIVsmmFTq showed acceptable growth on total PBMCs,
whereas the lineage 6 strain showed significantly better in
vitro growth on CD8+-depleted Rh PBMCs (data not shown).
Altogether, our data show that primary SIVsmm isolate in
Fig. 7. Comparison between in vitro and in vivo SIVsmm replication in Rh. Sixteen Rh were infected with 6 different primary SIVsmm isolates belonging to different
lineages (red—Lineage 1; purple—Lineage 2; turquoise—Lineage 3; blue—Lineage 4; orange—Lineage 5; light green—Lineage 6). The in vitro replication was
evaluating by quantifying the production of P27 Ag in supernatants over 3 weeks of infection (a); the in vivo replication was quantifying by measuring the P27
antigenemia during primary infection (days 0–28 post-inoculation) (b) or by quantifying plasma SIVsmm loads over the same period (c).
264 R. Gautam et al. / Virology 362 (2007) 257–270vitro replication profiles on Rh PBMCs have no predictive
value for the dynamics of in vivo replication in Rh.
Discussion
We have performed an extensive in vitro characterization of
primary SIVsmm isolates belonging to 6 different lineages. We
show that (1) these viruses uses CCR5 as a main co-receptor for
virus entry; (2) primary SIVsmm isolates efficiently replicate in
Hu PBMCs; (3) primary SIVsmm isolates replicate at low levels
in PTM PBMCs and the replication efficacy significantly im-
proves on CD8+-depleted PTM PBMCs; (4) primary SIVsmm
strains show variable in vitro replication on Rh PBMCs but not
in Hu PBMCs; and (5) no correlation can be established between
the in vitro and in vivo replication patterns in Rh.
All primary SIVsmm isolates replicated at high titers in Hu
PBMCs and showed variable replication on Hu cell lines. This
result confirms previous reports (Chen et al., 1995; Fultz et al.,
1986; Marx et al., 1991) and is highly significant because
SIVsmm was cross-species transmitted to humans in several
instances during the last century and is the root cause of HIV-2(Chen et al., 1997a; Damond et al., 2004; Gao et al., 1992,
1994; Marx, 2005; Yamaguchi et al., 2000). Our results showed
that all primary SIVsmm isolates have a consistent ability to
efficiently replicate in vitro on human PBMCs, suggesting an
ongoing risk for human exposed to SIVsmm in the endemic
area. Note, however, that only two of the eight documented
cross-species SIVsmm transmission to humans resulted in
epidemics (Damond et al., 2001), whereas the remaining cases
seem to be epidemiological dead-ends, probably as a result of
the immune control by the human hosts (Gao et al., 1994) or
action of specific yet undetermined host restriction factors
(Huthoff and Malim, 2005; Ylinen et al., 2005). In this context,
our results suggest that the inability of SIVsmm strains to
establish themselves as human pathogens is not due to cellular
host restriction factors, since all the primary SIVsmm isolates
tested here and in previous studies (Chen et al., 1995, 1996)
replicated efficiently on PBMCs originating from different
human blood donors, but to other defense barriers, such as
effective immune responses. This may be an important result,
because it has been suggested that human exposure to a plethora
of SIVs in Central and West Africa may result in the emergence
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show that in vitro replication of SIVs on Hu PBMCs may not
have predictive value for the ability of a cross-species
transmitted pathogen to establish itself as a new pathogen in
the new host. In this context, the risk of emergence of new
pathogens following exposure to SIV-infected monkeys and
apes in Africa may need to be reconsidered, especially since
numerous SIVs do not even have the ability to replicate on
human PBMCs (Beer et al., 1999; Emau et al., 1991; Osterhaus
et al., 1999) (Apetrei, unpublished observations).
Primary SIVsmm isolates also replicated at moderate levels
in PTM PBMCs. The efficacy of replication dramatically
improved on CD8+-depleted PTM PBMCs. The ability to
replicate on PTM PBMCs in vitro is not surprising because
previous studies reported a higher susceptibility to SIVsmm
infections in PTMs than Rh. The best known example is the
strain SIVsmmPBj and its derivatives, which is extremely
virulent in different species of macaques and even in SMs
(Fultz, 1994; Fultz et al., 1989). This strain was derived from a
virus isolated from PTMs infected with SIVsmm9 (McClure et
al., 1989). Also, unlike Rh, which progress to AIDS only when
infected with SIVsmm and show a certain resistance to other
cross-species transmitted SIVs (Osterhaus et al., 1999; Smith et
al., 1998; Takehisa et al., 2001), PTMs are more susceptible to
cross-species transmitted SIV infections. To date, PTMs were
shown to develop AIDS when infected with SIVagm (Goldstein
et al., 2005; Hirsch et al., 1995; Pandrea et al., submitted for
publication), SIVsun (Beer et al., 2005), and SIVlhoest (Beer et
al., 2005; Hirsch et al., 1999). In contrast, Rh infected with
SIVagm or with SIVrcm, SIVmnd-2, and SIVtal replicated these
viruses transiently and then cleared the infections (Osterhaus et
al., 1999; Pandrea et al., submitted for publication; Smith et al.,
1998; Takehisa et al., 2001).
The most notable result of this study is the variable
susceptibility of Rh-PBMCs to primary SIVsmm isolates.
Numerous studies reported that SIVsmm is pathogenic in Rh
upon direct inoculation from naturally infected SMs (McClure
et al., 1989; Murphey-Corb et al., 1986; Novembre et al.,
1998). In Rh, SIVsmm induces persistent infection, with
variable clinical expression. Serially passaged pathogenic
SIVmac or SIVsmm543-3 strains are able to induce severe
infection in which most of the monkeys progress to AIDS
within 1 year post-inoculation (Hirsch et al., 1997; Westmore-
land et al., 1999). Less adapted strains, or strains derived
directly from SMs generally induce a less pathogenic
infection, characterized by a better control of viral loads
and longer and variable incubation period (Hirsch and
Johnson, 1994) (Apetrei, unpublished data). Whatever the
outcome of these infections in Rh, most of the Rh exposed to
SIVsmm replicate the virus at high levels during the primary
infection, in the absence of any immune control. Conversely,
our in vitro results showed a limited ability of primary
SIVsmm isolates to replicate in Rh PBMCs. This limited
replication is not virus related, because there is significant
variability in the replicative capacity of the same viral strain
on PBMCs from different Rh. When CD8+ cells are depleted
from the PBMCs, the efficacy of the in vitro replication ofprimary SIVsmm isolates on Rh cells does not significantly
improve in resistant macaques (data not shown). Moreover,
we demonstrated the ability of primary SIVsmm isolates to
infect two types of antigen-presenting cells, MDDCs and
MDMs. Both MDDC and MDM data show that viral
replication in vivo may imply involvement of some other
immune cell populations and complex cellular interactions,
which may explain the differences observed between replica-
tion patterns of primary SIVsmm isolates in vitro and in vivo.
Note that this variable in vitro replication of primary SIVsmm
isolates is specific for Rh PBMCs, in vitro replication of
SIVsmm strains being significantly more consistent in Hu
PBMCs.
Finally, to investigate the predictive value of in vitro
replication capacity for in vivo replication of these primary
SIVsmm isolates, we compared peak levels of virus production
in vitro and in vivo in the same animals. Previous studies
reported that the intrinsic susceptibility of Rh PBMCs to SIV
infection in vitro is predictive of viremia after SIV challenge
(Lifson et al., 1997). However, in our study, even though many
of the SIVsmm strains failed to replicate efficiently in vitro in a
donor macaque's PBMC, the majority resulted in robust
replication in vivo upon inoculation of this same Rh (Fig. 7).
Therefore, we concluded that the in vitro growth of SIVsmm
strains on Rh PBMCs is not predictive for virus replication in
vivo, showing that the in vitro results should always be
interpreted in the light of the in vivo data.
What is the significance of Rh-PBMC's variable suscept-
ibility to SIVsmm replication? We first hypothesized that the
lack of viral replication in vitro on Rh PBMCs is due to a high
number of CD8+ T cells in PBMC cultures inhibiting SIVsmm
growth (Goldstein et al., 2000). However, Rh CD8+-depleted
PBMCs cells still showed variable replication patterns between
Rh. To investigate if the lack of replication was due to a total
species-specific restriction of SIVsmm in some Rh (Huthoff and
Malim, 2005; Ylinen et al., 2005), we co-cultivated infected
MDDCs or MDMs with CD8+ Rh PBMCs. By using antigen-
presenting cells to infect CD8+-depleted Rh PBMCs, we
generated better results than when growing SIVsmm by
conventional methods. The fact that in vitro susceptibility of
Rh PBMCs varies widely may finally be explained by
differences in host susceptibility.
In summary, the present study provides a thorough
characterization of the in vitro growth of primary SIVsmm
isolates belonging to different lineages. By showing wide varia-
bility in the ability of Rh PBMCs to support in vitro replication
of SIVsmm strains, our study suggests that in vitro replication
has no predictive value for in vivo pathogenesis studies using
these strains. Our results thus confirm the importance of in vivo
studies for understanding the pathogenesis of AIDS.
Materials and methods
Strain selection
Eleven SIVsmm isolates were used in this study. Ten were
isolated from chronic naturally infected SMs housed at the
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M923, M935 (lineage1); M926, M946 (lineage 2); M940,
M949, M951 (lineage3); G932 (lineage 4); and D215 (lineage
6). Additionally, strain FTq (lineage 5) was isolated from a
naturally infected SM housed at the Yerkes National Primate
Research Center (YNPRC). All the SMs from which SIVsmm
strains were isolated were free of simian T-cell lymphotropic
virus (STLV).
All protocols and procedures for the animal studies were
reviewed and approved by the Tulane University Institutional
Animal Care and Use Committee (IACUC), and all
protocols and procedures for the human studies were ap-
proved by the Tulane University Institutional Review Board
(IRB).
PBMC isolation
PBMCs from both naturally SIVsmm-infected SMs and
from SIV-free SMs (n=5), Rh (n=13), pig-tailed macaques
(PTMs) (n=3), and humans (Hu) (n=10) were isolated by
density gradient centrifugation over lymphocyte separation
media (MP Biomedical, Irvine, CA). Briefly, blood was
layered over density gradient media in a ratio of 2:1 and
centrifuged at 18 °C at 400×g for 25 min. The monolayer
containing PBMCs was resuspended with RPMI1640 media
supplemented with 10% heat-inactivated fetal bovine serum
(FBS) and 1% penicillin–streptomycin (1 mg/ml, Invitrogen,
CA) for subsequent studies. Hu PBMCs were obtained from
Tulane University blood bank.
SIVsmm stock preparation
PBMCs (5×106) from infected and uninfected SMs were
stimulated with 10 μg/ml phytohemagglutinin (PHA) (Invitro-
gen, Carlsbad, CA) for 2 days, followed by overnight
incubation in interleukin-2 (IL-2) media, RPMI1640 medium
supplemented with 10% heat-inactivated FBS and IL-2 (20 U/
ml). Subsequently, PBMCs from SIVsmm-uninfected and
SIVsmm-infected SMs were co-cultured in IL-2 media for
5 weeks, and replication was monitored weekly by quantifying
the SIV P27 Gag antigen by ELISA (Zeptometrix Corp.,
Buffalo, NY) in supernatants. Virus stocks prepared from these
infected cells were kept at −80 °C for use in subsequent
infectivity studies. These experiments were performed in
triplicate, on PBMCs from five different SMs.
In vitro SIVsmm replication on human T-cell lines
Hu CD4+ T cell lines (MT2, SupT1, CEMss, CEMx174,
PM1, and Molt4clone8) were maintained in RPMI1640,
supplemented with 10% heat-inactivated FBS, and 1% peni-
cillin–streptomycin (1 mg/ml). For infection studies, 106 cells
were infected with supernatants produced on SM PBMCs,
corresponding to 4000 pg of P27 Ag in 12-well plates (Costar,
Corning, N.Y.). Cells were incubated for 4 h and then washed
extensively to remove cell-free virus. Virus production in culture
supernatants was monitored weekly by SIV P27 Ag captureassay (Zeptometrix). These experiments were performed in
triplicate, on PBMCs from one human subject.
Co-receptor assays on GHOST cells
The co-receptor usage of primary SIVsmm isolates was
determined on GHOST cells as previously described (Chen et
al., 1998a; Zhang et al., 2000). The GHOST cells expressed
CD4 alone or CD4 in combination with the following co-
receptors: CCR2b, CCR5, CXCR4, BOB/GPR15, Bonzo/
STRL33. Cells were cultured in complete Dulbecco's minimal
essential medium containing G418 (5 μg/ml), hygromycin
(1 μg/ml), and puromycin (1 μg/ml). GHOST cells expressing
only CD4 were used as controls; they were cultured in the
same medium except that puromycin was omitted. Expression
of the co-receptors on these cells was verified at the day of
infection. 2×105 cells were exposed to at least three distinct
infectious titers of each virus. Productive viral replication was
monitored by P27 measurement in the culture supernatants on
days 0, 2, 4, 6, and 9. Supernatants were clarified from cells by
short-term centrifugation. Several positive controls were
included: HIV-1 strain B117, which uses CXCR4, CCR5,
Bonzo, and Bob (Bjorndal et al., 1997); SIVmac239, which
uses CCR5 and Bonzo, and SIVrcm (Georges-Courbot et al.,
1998) as a CCR5 CXCR4 negative control because it has been
previously reported to specifically use CCR2 as its main co-
receptor (Chen et al., 1998b). Uninfected cells were used as a
negative control. Co-receptor studies were performed in
triplicate.
Infection of PBMC from different host species
PBMCs were isolated from nine blood donors, three PTMs,
and thirteen Rh blood samples, as described earlier. Freshly
isolated PBMCs were stimulated with 10 μg PHA per ml of
medium for 2 days followed by overnight incubation in IL-2
media. Activated PBMCs and resting PBMCs (5×106) were
infected with SIV stocks containing 4000 pg of P27 at 37 °C for
4 h; cells were then washed extensively to remove any cell-free
virus. Cells were maintained in IL-2 media for 7 weeks. Virus
production in culture supernatants was monitored weekly by
SIV P27 antigen capture assay.
Isolation and infection of CD8+-depleted cells
Hu-PBMCs, PTM-PBMCs, and Rh-PBMCs were depleted
of CD8+ cells employing a positive selection of the CD8+ T
cells (CD8 microbead kit, Miltenyi Biotech, Auburn, CA). The
CD8+-depleted cells were then stimulated with 10 μg/ml PHA
for 2 days, followed by overnight incubation in IL-2 media.
5×105 CD8+-depleted cells were incubated with 400 pg of
SIVsmm isolates for 4 h, followed by two washes to remove cell
free virus. For 4 weeks, one half of the supernatant was
collected every third day and replaced with fresh IL-2
containing media. Virus production in culture supernatants
was monitored by SIV P27 antigen capture assay. These expe-
riments were performed in triplicate.
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Rh MDDCs were generated using CD14+ monocytes,
positively selected by MACS Ab-conjugated magnetic bead
selection according to the manufacturer's protocol (Miltenyi
Biotech). Briefly, isolated CD14+ monocytes were placed into
six-well tissue culture plates at 106 cells in 2 ml of complete
(cRPMI) medium. Cells were cultured for 6 days in the
presence of 50 ng/ml of granulocyte/macrophage-colony
stimulating factor (GM-CSF) (Peprotech, Rockey Hill, NJ)
and 20 ng/ml of IL-4 (Peprotech) per ml. Cytokines were
replenished every other day by adding 2 ml of fresh medium
and cytokines. After 6 days, the floating cells and weakly
adherent cells were harvested by gently pipetting and used for
subsequent studies. The phenotype of the cultured cells was
monitored by flow cytometry. The following combinations of
mouse anti-human monoclonal Abs were used: Fluorescein
isothiocyanate (FITC)-labeled anti-CD14 (M5E2, BD Phar-
mingen, San Jose, CA), FITC-labeled anti-CD83 (HB15e; BD
Pharmingen), Phycoerythrin (PE)-labeled anti-CD86 (FUN-1;
BD Pharmingen), PE-labeled anti-DC-SIGN (CD209)
(120507, R&D Systems, Minneapolis, MN), Peridinin chlor-
ophyll A protein (PerCP)-labeled anti-HLA-DR (L243; BD
Pharmingen), and allophycocyanin (APC)-labeled anti-CD11b
(M1/70.15.11.5; Miltenyi Biotech). The cells were stained with
these reagents for 30 min at 4 °C, washed with PBS, and fixed
with 2.0% formaldehyde in PBS. Samples were collected on a
FACSCalibur flow cytometer (Becton Dickinson), and
acquired data were analyzed using FloJo software (Tree
Star). The culture cells were characterized by the CD14+,
CD11b+, CD83+/-, HLA-DR+++, CD86++, and DC-SIGN++
phenotype corresponding to immature DC.
In vitro infection of MDDC-T cell cultures
For the infection of MDDCs, 5×105 cells were incubated
with SIVsmm stocks containing 400 pg of P27 Ag in a total
volume of 500 μl at 37 °C for 4 h in eppendorf tubes. After the
incubation steps, cells were extensively washed to remove cell
free virus and were cultured for 3 weeks with or without
autologous CD8+-depleted Rh PBMCs in the presence of GM-
CSF (50 ng/ml) and IL-4 (20 ng/ml). Every 3 days, one half of
the supernatant was removed and replaced with fresh medium.
Supernatants were analyzed for SIV P27 Gag antigen by
ELISA. These experiments were performed in triplicate.
Generation of monocyte-derived macrophages (MDMs)
Rh MDMs were generated using CD14+ monocytes,
positively selected by MACS Ab-conjugated magnetic bead
selection according to the manufacturer's protocol (Miltenyi
Biotech). Recovered CD14+ monocytes were placed into six-
well tissue culture plates at 106 cells in 2 ml of cRPMI medium.
Cells were cultured for 6 days in the presence of 50 ng/ml of
macrophage-colony stimulating factor (M-CSF; Peprotech) and
20 ng/ml of IL-4. Cytokines were replenished every other day
by adding 2 ml of fresh medium and cytokines. At 7 days,adherent macrophages were collected with PBS containing
5 mM EDTA. The phenotype of the culture cells was checked
by measuring CD14, CD86, HLA-DR, and CD11b expression
by flow cytometry. The cultured cells expressed CD14++,
CD86++, HLA-DR+++, and CD11++.
In vitro infection of MDM-T cell cultures
For the infection of MDMs, the cells (5×105) were infected
with SIVsmm stocks corresponding 400 pg of P27 Ag at 37 °C
for 4 h. After this incubation step, cells were extensively
washed to remove cell free virus and were cultured for 3 weeks
with or without autologous CD8+-depleted Rh PBMCs in the
presence of GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). Every
3 days, one half of the supernatant was removed and replaced
with fresh medium. Supernatants were analyzed for SIV P27
Gag antigen by ELISA. These experiments were performed in
triplicate.
Comparison of in vivo and in vitro replication of primary
SIVsmm isolates in Rh
To investigate the significance of in vitro growth patterns of
primary SIVsmm isolates in Rh, we compared viral replication
in vivo and in vitro on a significant group of Rh. Sixteen
animals experimentally infected with different primary
SIVsmm isolates were included. They received SIVsmm
M923-lineage 1 (Rh CA59 and AP31), SIVsmm946-lineage 2
(Rh AT80 and GO99), SIVsmmM951-lineage 3 (Rh DB28 and
BD51), SIVsmmG932-lineage 4 (Rh AT30), SIVsmmFTq (Rh
DV11, DD58, and DG24), and SIVsmmD215 (Rh AK41,
BE51, BV85, DD93, DG34, and DH44). The strains used to
infect these animals were grown in vitro on PBMCs collected
from each monkey prior to SIVsmm infection. The comparison
between in vitro and in vivo replication was done by measuring
the P27 Ag in supernatants and by quantifying the dynamics of
the P27 antigenemia during the primary SIVsmm infection of
Rh (days 0–28 post-inoculation). Also, in order top better relate
the dynamics of P27 antigenemia to SIVsmm replication in
vivo, we compared the P27 Ag dynamics in vivo to that of
plasma viral load during the primary SIVsmm infection of Rh.
Plasma viral loads were determined by bDNA (Bayer
Laboratory, Emeryville, CA).
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